News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference


6/2/2014 10:45:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG announced that Prof. Hermann Haller, Director of the Department of Nephrology and Hypertension at Hannover Medical School, was invited in his role as the principal investigator to present the full data of NOXXON’s phase IIa clinical trial with emapticap pegol (NOX-E36), for the treatment of diabetic nephropathy during the 2014 congress of the European Renal Association and the European Dialysis and Transplant Association.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES